Lexeo Therapeutics (LXEO) PT Lowered to $18 at Leerink Partners, 'we continue to see favorable risk/reward into 2H25'
Tweet Send to a Friend
Leerink Partners analyst Mani Foroohar lowered the price target on Lexeo Therapeutics (NASDAQ: LXEO) to $18.00 (from $19.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
